lenvatinib
Selected indexed studies
- Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy. (Biochim Biophys Acta Rev Cancer, 2020) [PMID:32659252]
- Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. (N Engl J Med, 2015) [PMID:25671254]
- Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy. (Liver Int, 2024) [PMID:38700443]
_Worker-drafted node — pending editorial review._
Connections
lenvatinib is a side effect of
Sources
- Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy. (2020) pubmed
- Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. (2015) pubmed
- Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy. (2024) pubmed
- Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3-ABCB1 Signaling in Hepatocellular Carcinoma. (2022) pubmed
- Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives. (2024) pubmed
- METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma. (2023) pubmed
- METTL3-m(6)A-EGFR-axis drives lenvatinib resistance in hepatocellular carcinoma. (2023) pubmed
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. (2015) pubmed
- Lenvatinib: A Review in Hepatocellular Carcinoma. (2019) pubmed
- Lenvatinib in Management of Solid Tumors. (2020) pubmed